This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A protein kinase inhibitor composition comprising a compound having the chemical formula:



wherein R_1, R_2, and R_3 is each independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, OH, amine, thioether, SH, halogen, hydrogen, NO_2 and NH_2; and R_5 is an alkylaryl comprising an alkyl group and an aryl group having the following structure:



wherein X_1, X_2, X_3, X_4, and X_5 is each independently selected from the group consisting of hydrogen, halogen, alkyl, trihalomethyl, and NO_2.

2. (Currently Amended) The composition of claim 1, wherein ~~said~~ R_1 and ~~said~~ R_2 ~~is~~ and OH, and ~~said~~ R_3 is hydrogen~~, and said compound significantly inhibits HER-2 activity~~.

3. (Original) The composition of claim 2, further comprising a physiologically acceptable carrier.

4. (Original) The composition of claim 1, wherein said compound is M13.

Claims 5-31 (Cancelled)

32. (Currently Amended) A method of treating a patient having a cell proliferation disorder by administering to said patient a therapeutically effective amount of a compound of the formula~~The method of claim 30 wherein said compound has the chemical formula~~:





ıe group consisting of SH, halogen, hydrogen, NC

R_5 is an alkylaryl comprising an alkyl group and an aryl group having the following structure:



wherein X_1, X_2, X_3, X_4, and X_5 is each independently selected from the group consisting of hydrogen, halogen, alkyl, trihalomethyl, and NO_2.

Claims 33-35 (Cancelled)

36. (Original) The method of claim 30, wherein said disorder is characterized by inappropriate activity of EGF-R.

37. (Original) The method of claim 31, wherein said cell proliferative disorder is a cancer.

38. (Original) The method of claim 37, wherein said cancer is selected from the group consisting of breast carcinomas, stomach adenocarcinomas, salivary gland adenocarcinomas,

endometrial cancers, ovarian adenocarcinomas, gastric cancers, colorectal cancers, and glioblastomas.

39. (Original) The method of claim 38, wherein said cancer is breast cancer.

Claims 40-43 (Cancelled)

44. (New) The composition of claim 1, wherein R_1 and R_3 are isopropyl and R_2 is hydroxy.

45. (New) The composition of claim 44, further comprising a physiologically acceptable carrier.

46. (New) The composition of claim 1, wherein said compound is M24.

47. (New) The method of claim 32, wherein R_1 and R_2 are OH and R_3 is hydroxy.

48. (New) The method of claim 32, further comprising a physiologically acceptable carrier.

49. (New) The method of claim 32, wherein said compound is M13.

50. (New) The method of claim 32, wherein R_1 and R_3 are isopropyl and R_2 is hydroxy.

51. (New) The method of claim 32, further comprising a physiologically acceptable carrier.

52. (New) The method of claim 32, wherein said compound is M24.

53. (New) A method of treating a patient having a cancer characterized by over-activity of HER2, wherein said cancer is sensitive to treatment by a compound of either claim 1 or claim 32, comprising administering to said patient a therapeutically effective amount of a compound of either claim 1 or claim 32.

54. (New) A method of treating a patient having a cancer characterized by inappropriate activity of EGFR, wherein said cancer is sensitive to treatment by a compound of either claim 1 or claim 32, comprising administering to said patient a therapeutically effective amount of a compound of either claim 1 or claim 32.